Summary by Futu AI
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has reported a series of financial transactions and corporate actions in a recent Form 8-K filing with the SEC. The company entered into a Securities Purchase Agreement on April 4, 2024, with an institutional accredited investor, selling 1,500 shares of Series B Convertible Preferred Stock and warrants to purchase up to 3,300,000 shares of common stock. The initial closing occurred on April 5, 2024, with subsequent closings scheduled, including the most recent third closing on June 28, 2024, where 750 shares of Series B Preferred Stock and additional warrants were sold. The company has also amended the Purchase Agreement to adjust the closing schedules and remove an option for the investor to purchase additional Series B Preferred Stock. Furthermore, the company's...Show More